NCT02521246View on ClinicalTrials.gov

Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

August 31, 2017

Conditions
Essential Arterial Hypertension
Interventions
DRUG

Candesartan + Chlorthalidone

DRUG

Candesartan + Chlorthalidone

DRUG

Losartan+hydrochlorothiazide

Sponsors

Lead Sponsor

EMS
All Listed Sponsors
lead

EMS

INDUSTRY

NCT02521246 - Efficacy and Safety of Candesartan Associated With Chlorthalidone Versus Losartan Associated With Hydrochlorothiazide (Hyzaar®) in Essential Hypertension Control | Biotech Hunter | Biotech Hunter